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with	secondary	 immunodeficiency	 (SID)	due	to	B‐cell	 lymphoproliferative	diseases	






eloma,	 76%	with	 chronic	 lymphocytic	 leukemia,	 and	 69%	with	 non‐Hodgkin	 lym‐
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1  | INTRODUC TION
Hypogammaglobulinemia	 is	 characterized	 by	 a	 decrease	 in	 func‐
tional	or	total	serum	immunoglobulin	(Ig)	levels	and	can	lead	to	im‐




treatments.1	 Patients	with	 B‐cell	 lymphoproliferative	 diseases	 are	
particularly	 prone	 to	SID	due	 to	 immunodeficiency	 caused	by	 the	
underlying	malignancies	or	the	chemoimmunotherapies	used	to	treat	
the	malignancies.	 Standard	 treatment	protocols	of	NHL,	MM,	 and	
CLL	include	conventional	chemotherapeutics	such	as	cyclophospha‐
mide.	The	spectrum	of	treatments	is	entity‐dependent	and	extended	
by	 targeted	 therapies,	which	 are	 associated	with	 specific	 immune	




recent	 targeted	 therapies,	 such	 as	 Bruton’s	 tyrosine	 kinase	 and	
Phosphoinositide	 3‐kinase	δ	 inhibitors,	 are	 broadly	 applied	 in	CLL	












Treatment	 of	 immunodeficiency	 by	 immunoglobulin	 replace‐
ment	therapy	 (IgRT)	 is	well	established	 in	PID	due	to	proven	effi‐
cacy	and	safety.11	 In	SID,	despite	being	more	prevalent	 than	PID,	
clinical	 data	 on	 IgRT	 are	 limited.	 Evidence	 for	 the	 use	 of	 IgRT	 in	
CLL	 and	MM	 is	 predominantly	 based	 on	 clinical	 trials	 performed	
20‐30	years	 ago,	 before	 modern	 immunosuppressive	 therapies	




Immunoglobulin	 replacement	 therapy	may	 be	 administered	 in‐
travenously	 (IV)	or	subcutaneously	 (SC).	 In	PID,	both	routes	of	ad‐





SCIG	might	 have	 several	 advantages	 over	 IVIG	 to	 some	 patients.	
SCIG	does	not	require	venous	access	and	allows	more	flexible	and	
convenient	self‐administration	at	home	than	IVIG.12	SCIG	has	been	
associated	with	 an	 improvement	 in	 perceived	 health‐related	 qual‐
ity	of	life.12,19	Additionally,	pharmacokinetics	may	be	preferable,	as	
SCIG	treatment	 leads	to	higher	and	more	stable	 IgG	trough	 levels,	









addition	 to	 promoting	 off‐label	 use,	 differences	 in	 current	 recom‐
mendations	highlight	open	questions	regarding	the	selection	of	pa‐
tients	who	might	benefit	from	IgRT,	such	as	Ig	and	Ig	subclass	serum	
levels,	 testing	 specific	 antibody	 responses,	 test	 immunization,	 and	
infection	history.	In	a	2014	European	consensus	statement,	the	de‐
termination	 of	 serum	 Ig	 concentrations	 and	 the	 levels	 of	 specific	
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Additional	open	questions	 include	 Ig	dose,	 the	monitoring	of	 Ig	
trough	 levels	during	 therapy,	 and	 criteria	 for	 the	duration	of	 treat‐
ment.	There	is	no	consensus	on	the	duration	of	IgRT.	Re‐evaluation	



















TA B L E  1  Respondent	and	patient	characteristics
Parameter Canada France Germany Italy Spain UK USA Pooled




16	(53) 21	(70) 23	(77) 21	(70) 19	(63) 23	(77) 25	(50) 148	(64)
Immunologist 5	(17) 1	(3) 1	(3) 3	(10) 9	(30)a  3	(10) 10	(20) 32	(14)
Internal	medicine 3	(10) 5	(17) 2	(7) 3	(10) 1	(3) 2	(7) 10	(20) 26	(11)
Pediatrician 6	(20) 2	(7) 4	(13) 3	(10) 1	(3) 1	(3) 5	(10) 22	(10)
Other 0	(0) 1	(3) 0	(0) 0	(0) 0	(0) 1	(3) 0	(0) 2	(1)
Clinical	experience,	n	(%)
<5 y 3	(10) 1	(3) 0	(0) 5	(17) 3	(10) 1	(3) 5	(10) 18	(8)
5‐15	y 16	(53) 12	(40) 16	(53) 11	(37) 17	(57) 21	(70) 24	(48) 117	(51)




24	(80) 29	(97) 29	(97) 28	(93) 26	(87) 27	(90) 45	(90) 208	(90)
Number	of	patients	cared	for	per	respondent,	n,	median
CLL 15 40 50 30 23 35 20 213
MM 15 39 46 45 21 38 15 219
NHL 10 33 60 50 33 31 25 242
Other	lymphoprolifera‐
tive	diseases
10 20 23 35 20 18 15 141
All	indications 50 132 179 160 97 122 75 815
Patients	cared	for	with	severe	or	recurring	infections,	n	(%	patients)
CLL 398	(34) 335	(28) 655	(35) 730	(29) 461	(38) 280	(21) 496	(25) 3355	(30)
MM 263	(26) 371	(30) 454	(29) 521	(25) 314	(31) 292	(23) 489	(26) 2704	(27)
NHL 300	(26) 341	(26) 677	(27) 531	(27) 326	(26) 219	(18) 400	(20) 2794	(24)
Other	lymphoprolifera‐
tive	diseases
193	(27) 241	(24) 399	(24) 424	(27) 311	(27) 135	(19) 368	(22) 2071	(24)
Patients	cared	for	with	hypogammaglobulinemia	(IgG	<	4	g/L),	n	(%	of	patients)
CLL 369	(32) 433	(36) 631	(34) 911	(36) 438	(36) 366	(27) 609	(31) 3721	(33)
MM 241	(24) 446	(36) 403	(25) 720	(35) 339	(34) 405	(32) 505	(27) 3043	(30)
NHL 247	(22) 362	(28) 593	(24) 490	(25) 347	(28) 173	(14) 478	(24) 2669	(23)
Other	lymphoprolifera‐
tive	diseases
196	(28) 331	(32) 365	(22) 379	(24) 319	(28) 112	(16) 396	(23) 2086	(25)
CLL,	chronic	lymphocytic	leukemia;	MM,	multiple	myeloma;	NHL,	non‐Hodgkin	lymphoma.
aIncludes	four	physicians	classified	as	allergists/immunologists.	






































































































































































































































































































































































































































































































































































































































































































































































































































































     |  451NA et Al.
2  | METHODS
The	 online	 survey	 was	 conducted	 in	 January	 and	 February	 2018	
and	was	open	to	physicians	from	the	United	States,	Canada,	the	UK,	
France,	Italy,	Spain,	and	Germany.	Qualified	physicians	included	im‐















50%	of	 physicians	 in	 all	 countries	 and	90%	of	 all	 participants	 had	
5	years	of	clinical	experience	or	more.	Overall,	surveyed	physicians	
spent	 the	major	part	 of	 their	 time	 in	university/teaching	hospitals	
and	less	in	other	hospitals,	private	practices,	and/or	outpatient	clin‐
ics.	Of	 all	 participants,	 59%	 (N	=	135)	 practiced	exclusively	 in	one	
care	setting	with	64%	of	those	(N	=	87)	working	exclusively	in	uni‐
versity/teaching	hospitals.






On	 average,	 CLL	 and	MM	 patients	 were	 more	 likely	 to	 develop	
severe	or	 recurring	 infections	 (30%	and	27%)	 than	patients	with	
NHL	 or	 other	 lymphoproliferative	 diseases	 (24%	 each;	 Table	 1).	
Similarly,	 CLL	 and	MM	patients	were	more	 likely	 to	 develop	 hy‐
pogammaglobulinemia	(33%	and	30%),	defined	as	IgG	levels	<4	g/L,	
than	those	with	NHL	or	other	 lymphoproliferative	diseases	 (23%	
and	 25%).	 There	 was	 some	 variation	 across	 countries	 (Table	 1).	
Hematopoietic	 stem	 cell	 transplantation	 (HSCT)	 was	 performed	
in	14%,	25%,	19%,	and	15%	of	patients	with	CLL,	MM,	NHL,	and	
other	 lymphoproliferative	 diseases,	 respectively.	 Patients	 with	








3.3 | Monitoring and diagnostic practice
Overall,	 serum	 Ig	 levels	were	measured	 in	 83%	 of	MM	 patients,	
76%	 of	 CLL	 patients,	 69%	 of	NHL	 patients,	 and	 69%	 of	 patients	
with	other	lymphoproliferative	diseases	(Table	2).	Ig	levels	in	NHL	
patients	 or	 with	 other	 lymphoproliferative	 diseases	 were	 more	
frequently	measured	by	physicians	spending	at	 least	50%	of	their	
time	in	the	university	setting	in	Canada,	Spain,	and	Italy	(in	about	
80%	of	 their	 patients).	Nearly	 all	 physicians	measured	 IgG	 levels	
(92%‐100%	across	all	countries),	and	most	physicians	measured	IgA	
and	 IgM	 levels	 (68%‐90%	 across	 all	 countries;	 Table	 2).	 IgG	 sub‐
classes	 were	 frequently	 measured	 by	 physicians	 in	 Spain	 (60%),	
Italy	 (43%),	and	the	United	States	 (40%),	and	by	nearly	a	 third	of	
physicians	in	Germany,	Canada,	and	the	UK.	Most	physicians	(82%)	
F I G U R E  1   Infection	prophylaxis	across	all	countries	in	patients	with	hypogammaglobulinemia	(USA	[N	=	50],	Canada,	the	UK,	France,	
Italy,	Spain,	and	Germany	[N	=	30	each])






countries	 (Table	 2).	 Over	 one‐third	 of	 respondents	 (38%)	 did	 not	
measure	 specific	 antibody	 responses	 in	 general.	 Spanish,	 Italian,	






nization	 with	 high	 variability	 observed	 between	 countries.	 While	




3.4 | Choice of infection prophylaxis




across	most	countries,	but	 there	was	some	variation	 (Table	S1).	 In	
Italy,	Germany,	Spain,	and	the	United	States,	Ig	use	in	patients	with	
hypogammaglobulinemia	 was	 generally	 above	 average.	 The	 com‐
bined	use	of	Ig	and	antibiotics	was	slightly	more	widespread	in	the	
United	 States	 compared	 with	 Europe.	 Concomitant	 use	 of	 Ig	 and	
antibiotics	was	particularly	rare	in	the	UK,	where	Ig	use	was	much	








3.5 | Treatment with IgRT by indication
The	average	proportion	of	patients	reportedly	treated	with	Ig	alone	
and/	or	in	parallel	with	antibiotics	was	comparable	across	CLL	(32%),	
MM	 (33%),	 NHL	 (25%),	 and	 other	 lymphoproliferative	 diseases	
(26%),	 with	 approximately	 one‐quarter	 to	 one‐third	 of	 patients	
being	 treated	 across	 each	 indication	 (Figure	 2).	 There	were	 some	
regional	 differences	 in	 the	 frequency	 of	 IgRT	 across	 indications.	
Patients	in	Italy	and	the	United	States	were	more	frequently	treated	
with	Ig	across	all	indications.	In	the	UK,	considerably	fewer	patients	
received	 IgRT,	 particularly	 in	 NHL	 (11%)	 and	 other	 lymphoprolif‐
erative	 diseases	 (6%).	 In	 contrast,	 patients	 in	 Italy	 and	 the	United	
States	were	more	 frequently	 treated	with	 Ig	across	all	 indications.	
Furthermore,	US	physicians	practicing	at	least	50%	of	their	time	in	









3.6 | Route of administration and dose
The	reported	use	of	SCIG	was	highest	in	France	(34%)	followed	by	







Over	 80%	 of	 physicians	 prescribed	 Ig	 regardless	 of	 the	 season.	
The	reported	mean	Ig	treatment	duration	was	comparable	across	
countries	 and	 indications	with	 10‐12	months,	 ranging	 from	 1	 to	
60	months	 (Table	 S2).	 Physicians	 in	 Italy	 reported	 the	 shortest	
treatment	durations	across	all	indication	with	a	mean	of	7	months,	
probably	due	to	tighter	cost	control	in	these	countries.	The	main	
reasons	 reported	 for	 discontinuing	 Ig	 therapy	were	 no	 infection	
for	 12	months	 and	 adequate	 specific	 antibody	 response	 by	39%	
of	physicians,	 followed	by	no	 infections	 for	6	months	by	26%	of	













used	 Ig	more	 often	 than	 physicians	 before	 any	 infection	 occurred	








SIGNS	 study,	 and	 a	 survey	 among	British	 and	 Irish	 immunologists	
on	the	prescription	practice	of	IgRT	in	SID.23,24	The	present	online	
survey	of	230	physicians	identifies	a	discrepancy	between	approved	
indications,	 published	 recommendations,	 and	 daily	 routine	 in	 the	
treatment	of	SID	in	patients	with	hematological	malignancies	on	an	
international	level.
Approved	 indications	 for	 Ig	 products	 differ	 between	 countries.	
In	Canada,	 IVIG	and	SCIG	 concentrates	 are	 generally	 indicated	 for	
use	 in	 SID.25,26	 In	 the	EU,	 as	of	2019	 the	 approved	 indications	 for	
IVIG	in	SID	have	been	widened	from	patients	with	CLL,	MM	and	pa‐










approved	 indications	 in	 the	 corresponding	 country.	 For	 example,	
in	 the	United	States,	 the	American	Academy	of	Allergy,	Asthma	&	
Immunology	 (AAAAI)	 recommend	 that	 treatment	 should	 be	 con‐
sidered	 in	 patients	 with	 CLL	 or	 MM,	 after	 lymphoma	 treatment	
with	B‐cell‐depleting	therapies,	and	 in	patients	who	are	hypogam‐
maglobulinemic	with	 recurrent	bacterial	 infections	 and	 subprotec‐
tive	antibody	levels	after	immunization	against	diphtheria,	tetanus,	
or	pneumococcal	 infection.32	 In	Germany,	prophylactic	use	of	 Ig	 is	
recommended	 in	hypogammaglobulinemic	patients	with	malignant	
lymphoma,	MM,	and	chronic	immunosuppression	with	at	least	three	










cies	who	have	had	a	 recent	 life‐threatening	 infection	or	 recurrent	
episodes	of	clinically	significant	infections	(eg,	pneumonia),	if	these	
infections	are	thought	to	be	caused	by	low	levels	of	polyclonal	Ig.22
Treatment	 application	 was	 comparable	 across	 the	 countries,	
indicating	 that	 country‐specific	 approval	 status	of	 Ig	 concentrates	
does	 not	 influence	 the	 daily	 practice	 of	 physicians.	 Despite	 IgRT	
not	being	approved	for	malignancies	other	 than	CLL	 in	 the	United	
States	and	additionally	for	MM	in	Europe	at	the	time	of	the	survey,	
serum	Ig	 levels	were	widely	monitored	across	CLL,	MM,	NHL,	and	
other	 lymphoproliferative	 diseases	 and	 IgRT	 administered	 across	
all	these	malignancies.	In	the	United	States,	which	has	the	most	re‐
stricted	 indication,	 IgRT	was	prescribed	equally	 in	CLL,	MM,	NHL,	
and	other	lymphoproliferative	diseases	and	used	considerably	more	
frequently	within	each	 indication	 than	generally	 in	Europe	 (except	









proportion	 of	 patients	 with	 NHL	 receiving	 infection	 prophylaxis	
with	 Ig	 was	 considerably	 lower	 than	 the	 proportion	 of	 patients	
with	 severe	 or	 recurring	 infections.	 This	 indicates	 that	 patients	










A	 recent	 expert	 opinion	 on	 prophylactic	 IgRT	 in	 SID	 recom‐
mended	 against	 routine	 measurement	 of	 IgG	 subclasses	 due	 to	
the	 low	 incidence	of	pure	 IgG	subclass	deficiency	and	the	 limited	
evidence	for	correlation	between	infection	rates	and	low	levels	of	
IgG	subclasses	in	patients	with	normal	IgG	levels.11	In	contrast,	phy‐





antibody	 responses,	 while	 immunologists	 were	much	more	 likely	
to	 measure	 specific	 antibody	 responses.	 Contrary	 to	 recommen‐
dations	 to	 systematically	 perform	 test	 immunizations	 in	 patients	
with	 SID,	 only	 one‐third	 (33%)	 of	 surveyed	 physicians	 did	 so	 on	
average.11	Over	two‐thirds	(68%)	of	immunologists	performed	test	










fection	occurs	 (47%),	 and	even	before	 any	 infection	occurs	 (33%).	







The	 high	 reported	 use	 of	 prophylactic	 antibiotics	 in	 the	UK	 is	











The	 average	 initial	monthly	 starting	dose	of	 IgG	was	0.35	g/
kg	 BW,	 which	 lies	 in	 the	 range	 of	 0.2‐0.4	g/kg	 BW	 stated	 in	
most	 guidelines.	 In	 Europe,	 a	 dose	 of	 0.2‐0.4	g/kg	 BW	 every	
3‐4	weeks	 is	 recommended	 in	 the	 current	 IVIG	 core	 Summary	
of	 Product	 Characteristics.30	 Similarly,	 Canadian	 recommen‐
dations	 state	 0.4	g/kg	 BW	 every	 3	weeks	 with	 re‐evaluation	
every	 4‐6	months.22	 In	 contrast,	 UK	 clinical	 guidelines	 for	 Ig	
use	 (Department	 of	Health)	 have	modified	 the	 dose	 recommen‐
dation	 from	0.4	g/kg	 BW/mo	 to	 “achieve	 an	 IgG	 trough	 level	 of	
at	 least	 the	 lower	 limit	 of	 the	 age‐specific	 serum	 IgG	 reference	
range,”	while	British	guidelines	for	supportive	care	in	MM	suggest	
a	dose	of	IVIG	of	0.5	g/kg	BW	administered	every	month	for	up	to	
6	months.35,36	 Immunologists	 (n	=	32)	 tended	to	prescribe	higher	






Comparable	 to	 numbers	 reported	 for	 clinical	 practice	 in	
Germany,23	over	80%	of	physicians	used	IgRT	regardless	of	season.	
This	contrasts	with	recommendations	by	Agostini	et	al11	who	sug‐
gest	 seasonal	 discontinuation	 of	 treatment	 during	 late	 spring	 and	





patient	 records.	 In	 addition,	 the	proportion	of	patients	with	hy‐
pogammaglobulinemia	 and/	 or	 severe	 infections	 as	 separate	 or	
concomitant	events	was	not	analyzed.	Furthermore,	it	might	be	of	
interest	to	further	stratify	the	reported	data	by	diseases	grouped	
as	 “other	 lymphoproliferative	 diseases.”	 This	 study	 did	 not	 cap‐
ture	 data	 on	 chemotherapeutic	 medication	 used	 to	 treat	 the	
different	hematological	malignancies.	 In	 future	 studies,	 it	would	
be	 interesting	 to	assess	how	different	B‐cell	 targeting	 therapies	
across	 the	 investigated	disease	entities	 impact	on	 the	 incidence	
and	management	of	SID.
     |  455NA et Al.
5  | CONCLUSIONS
The	 survey	 revealed	 discrepancies	 among	 daily	 practice,	 clinical	
practice,	guideline	recommendations,	and	currently	approved	 indi‐





Despite	 regional	 indication	 differences,	 IgRT	 use	 was	 overall	
comparable	 across	 the	 countries.	 Moreover,	 although	 IgRT	 is	 not	
indicated	 for	 SID	 in	 hematological	malignancies	other	 than	CLL	 in	
the	 United	 States	 and	 CLL	 and	MM	 in	 Europe,	 physicians	 widely	
used	 IgRT	 in	 MM,	 NHL,	 and	 other	 hematological	 diseases.	 High	
regional	 variability	 and/or	 deviations	 from	 current	 treatment	 rec‐
ommendations	were	observed	in	the	monitoring	of	IgG	subclasses,	
measurement	of	 specific	 antibody	 responses,	 performance	of	 test	
immunization,	 and	 treatment	duration.	Overall,	 immunologists	 fol‐
lowed	 recommendations	 to	 measure	 specific	 antibody	 responses	
and	perform	test	 immunizations	much	more	closely	 than	hematol‐
ogists/oncologists,	 suggesting	 that	 closer	 collaboration	 between	
immunologists	and	hematologist/oncologists	could	be	beneficial	for	
the	management	of	SID.	This	large,	international	survey	of	different	
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